Results 71 to 80 of about 21,434 (231)

Evolving national dementia policies in the OECD: Prevention, diagnosis, and care

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract Dementia incurs yearly costs of nearly 1.3 trillion US dollars worldwide, projected to rise significantly in the coming decades due to population aging. This policy review provides an overview of the latest national dementia strategies, diagnostic guidelines, and treatment guidelines across 38 Organisation for Economic Co‐operation and ...
Soohyun Kim, Judit Rauet‐Tejeda, Ricarda Milstein, Jinkook Lee, Ana Llena‐Nozal   +4 more
wiley   +1 more source

Obsessive–compulsive disorder induced by donepezil in a patient with Alzheimer's disease

PCN Reports
Background Donepezil, an acetylcholinesterase inhibitor commonly used to treat Alzheimer's disease (AD), is generally well tolerated. There have been no previous reports on donepezil‐induced obsessive–compulsive disorder (OCD).
Kohei Echizen, Daisuke Hirose
doaj   +1 more source

Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in AppNL‐G‐F KI mice

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Whether cholinergic activity in the septohippocampal network affects cognitive dysfunction via hippocampal cholinergic neurostimulating peptide (HCNP) in Alzheimer's pathogenesis remains unclear. METHODS An Alzheimer's pathogenesis by mutation in amyloid‐beta precursor protein gene (AppNL‐G‐F) knock‐in (KI) and HCNP precursor ...
Yo Tsuda, Yuta Madokoro, Kengo Suzuki, Takuya Ooba, Toyohiro Sato, Yuto Uchida, Itsumi Nagai‐Arakawa, Takashi Saito, Hideaki Hara, Hideki Hida, Noriyuki Matsukawa   +10 more
wiley   +1 more source

Donepezil for dementia due to Alzheimer's disease

, 2018
Background Alzheimer's disease is the most common cause of dementia in older people. One approach to symptomatic treatment of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by blocking the action of the enzyme responsible ...
Richard J Harvey, Birks, JS, Birks, Jacqueline, Harvey, RJ, Jacqueline S Birks   +4 more
core   +2 more sources

Cortical synchrony is reduced in Alzheimer's disease and relates to arousal state

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION The brain is a complex dynamical system, influenced by arousal state. Cortical synchrony supports information processing and is disrupted in Alzheimer's disease (AD). Locus coeruleus (LC) integrity and pupillometry index arousal system structure and function.
Michael C. B. David, Emma‐Jane Mallas, Magdalena A. Kolanko, Martina Del Giovane, Danielle L. Kurtin, Ramin Nilforooshan, Karl A. Zimmerman, Cristina Bonet Olivares, Peter J. Lally, CR&T Group of UKDRI, David J. Sharp, Paresh A. Malhotra, Gregory Scott   +12 more
wiley   +1 more source

Donepezil-induced torsades de pointes without QT prolongation

, 2013
We report a case of torsades de pointes (TdP) induced by donepezil without QT prolongation. An 86-year-old woman was admitted to our hospital because of a syncopal attack. She had been treated for Alzheimer's disease with donepezil.
Akashi, Shintaro, Nakashima, Tadaaki, Shimizu, Akihiko, Ogawa, Hiroshi, Hadano, Yasuyuki, Miyazaki, Yosuke, 清水, 昭彦, Kimura, Masayasu, Mochizuki, Mamoru, Wakeyama, Takatoshi, Iwami, Takahiro   +10 more
core   +1 more source

Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) recently celebrated its 20th anniversary, reflecting two decades of major contributions to Alzheimer's research through open data sharing and longitudinal multimodal assessments. This review synthesizes 122 high‐impact studies using ADNI data or biospecimens from 2023 to mid‐2025 to ...
Dallas P. Veitch, Melanie J. Miller, Shaveta Kanoria, Paul S. Aisen, Laurel A. Beckett, Robert C. Green, Danielle J. Harvey, Clifford R. Jack Jr., William Jagust, Edward B. Lee, Kwangsik Nho, Rachel Nosheny, Ozioma C. Okonkwo, Richard J. Perrin, Ronald C. Petersen, Monica Rivera Mindt, Andrew J. Saykin, Leslie M. Shaw, Arthur W. Toga, Duygu Tosun, Susan M Landau, Michael W. Weiner, for the Alzheimer's Disease Neuroimaging Initiative   +22 more
wiley   +1 more source

Neuroprotection against vascular dementia after acupuncture combined with donepezil hydrochloride: P300 event related potential

Neural Regeneration Research, 2016
Acupuncture can be used to treat various nervous system diseases. Here, 168 vascular dementia patients were orally administered donepezil hydrochloride alone (5 mg/day, once a day for 56 days), or combined with acupuncture at Shenting (DU24), Tianzhu ...
Qiang Liu, Xiu-juan Wang, Zhe-cheng Zhang, Rong Xue, Ping Li, Bo Li   +5 more
doaj   +1 more source

Comparison of Adverse Drug Reactions with Donepezil

, 2010
Background. Since donepezil and memantine are currently used for treating Alzheimer’s disease, it is interesting to analyse, reassess and compare their safety profile in order to promote a better use. Methods.
Hervé Le-Louët, Samy Babai, Pascal Auriche   +2 more
core   +1 more source

Remote, self‐administered, smartphone cognitive testing in a registry‐based cohort: Feasibility, reliability, and validity findings

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract BACKGROUND Remote, smartphone‐based cognitive testing may improve access to cognitive assessments for Alzheimer's disease and related dementias. We evaluated the feasibility, reliability, and validity of unsupervised smartphone‐based cognitive tests in a registry‐based cohort.
Sreya Dhanam, Mark Sanderson‐Cimino, Jack Carson Taylor, Emily W. Paolillo, Ray Fregly, Winnie Kwang, Paul Maruff, Amy Wise, Hilary W. Heuer, Leah K. Forsberg, Joel H. Kramer, Bradley F. Boeve, Howard J. Rosen, R. Scott Mackin, Michael W. Weiner, Rachel L. Nosheny, Adam L. Boxer, Adam M. Staffaroni, and the Brain Health Registry   +18 more
wiley   +1 more source